Jacob Abraham, Robinson Lawrence L, Bortman Jared S, Yu Lianbo, Dodson Edward E, Welling D Bradley
Department of Otolaryngology-Head & Neck Surgery, Ohio State University School of Medicine, Columbus, OH 43210, USA.
Laryngoscope. 2007 Dec;117(12):2087-92. doi: 10.1097/MLG.0b013e3181453a07.
To determine nerve of origin, tumor size, hearing preservation rates, and facial nerve outcomes in a retrospective cohort study of patients undergoing translabyrinthine (TL), middle cranial fossa (MCF), and retrosigmoid/suboccipital (SO) approaches to vestibular schwannomas (VS).
Retrospective.
Chart review.
Patient charts from 231 TL, 70 MCF, 53 SO, and 5 combined TL/SO procedures for VS were evaluated in 356 patients. The inferior vestibular nerve (IVN) was the nerve of origin in 84 of 359 cases (23.3%), while the superior vestibular nerve (SVN) was the nerve of origin in 36 patients (10%). In 239 of 359 cases (66.6%), the nerve of origin was not identified. Forty patients undergoing hearing preservation surgery had hearing results and nerve of origin data available for review. Functional hearing (<50dB PTA and >50% speech discrimination) was preserved in 10 of 15 patients (75%) with SVN tumors, while only 7 of 25 patients (28%) with IVN tumors retained functional hearing. Facial nerve outcomes and nerve of origin were recorded simultaneously in 109 patients. Seventy-one of 74 patients (95%) patients with IVN tumors achieved a House-Brackmann (HB) grade I-III, while 35 of 35 patients (100%) with SVN tumors retained HB I-III facial function. Looking at tumor size versus hearing preservation, functional hearing was preserved in 22 of 49 patients (45%) with <1-cm tumors, and 4 of 20 patients (20%) with 1- to 1.5-cm tumors. For all cases with documented facial nerve function, HB I-III were achieved in 96% of SO, 94% of MCF, and 88% of TL procedures.
Our retrospective data indicated that IVN tumors were twice as common as SVN tumors. The nerve of origin did not affect facial nerve outcomes but did impact hearing preservation rates. Patients with tumors <1 cm in size had the best chance for hearing preservation. Overall facial nerve preservation was excellent with >90% achieving HB 1 to 3 function at final follow-up.
在一项对接受经迷路(TL)、中颅窝(MCF)和乙状窦后/枕下(SO)入路治疗前庭神经鞘瘤(VS)患者的回顾性队列研究中,确定肿瘤的起源神经、大小、听力保留率及面神经预后情况。
回顾性研究。
病历回顾。
对356例患者中231例TL、70例MCF、53例SO及5例联合TL/SO手术治疗VS的患者病历进行了评估。359例病例中,84例(23.3%)起源神经为下前庭神经(IVN),36例(10%)起源神经为上前庭神经(SVN)。359例病例中239例(66.6%)未明确起源神经。40例行听力保留手术的患者有听力结果及起源神经数据可供分析。SVN肿瘤患者中,15例有10例(75%)保留了功能性听力(纯音听阈<50dB且言语识别率>50%),而IVN肿瘤患者25例中仅7例(28%)保留了功能性听力。109例患者同时记录了面神经预后及起源神经情况。IVN肿瘤患者74例中有71例(95%)达到House-Brackmann(HB)分级I-III级,而SVN肿瘤患者35例中35例(100%)保留了HB I-III级面神经功能。观察肿瘤大小与听力保留情况,肿瘤<1cm的49例患者中有22例(45%)保留了功能性听力,肿瘤1至1.5cm的20例患者中有4例(20%)保留了功能性听力。对于所有记录了面神经功能的病例,SO入路96%、MCF入路94%、TL入路88%达到HB I-III级。
我们的回顾性数据表明,IVN肿瘤的发生率是SVN肿瘤的两倍。起源神经不影响面神经预后,但会影响听力保留率。肿瘤<1cm的患者听力保留机会最大。总体面神经保留情况良好,最终随访时超过90%达到HB 1至3级功能。